Key Insights

Highlights

Treatment Research

7 treatments under study, led by Azacitidine

Related Conditions

Often studied with 8 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
Phase 1 (1)
Phase 2 (2)

Trial Status

Withdrawn2
Recruiting2

Clinical Trials (4)

Showing 4 of 4 trials
NCT06116318WithdrawnPrimary

A Study of c-Kit Mutation as MRD in Acute Myeloid Leukemia

NCT03560908Phase 1Withdrawn

Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation

NCT06316960Phase 2Recruiting

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

NCT05009927Phase 2Recruiting

Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)

Showing all 4 trials

Research Network

Common Treatments

  • Azacitidine1
  • Dasatinib1
  • Avapritinib1
  • Idarubicin Hydrochloride1
  • Cytarabine1

Active Sponsors

  • Institute of Hematology & Blood Diseases Hospital, China2
  • Children's Hospital of Soochow University1
  • Centre Leon Berard1

Top Investigators

Related Conditions

  • Core Binding Factor Acute Myeloid Leukemia1
  • Refractory Aml1
  • Metastatic Gastrointestinal Stromal Tumor Gist1
  • Relapserecurrence1
  • T8211

Activity Timeline